| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HOOKIPA Pharma (NASDAQ:HOOK) reported quarterly losses of $(1.23) per share which missed the analyst consensus estimate of $(0....
- Reuters
HC Wainwright & Co. analyst Arthur He downgrades HOOKIPA Pharma (NASDAQ:HOOK) from Buy to Neutral.